Tg Therapeutics' 15-Min Chart Triggers MACD Death Cross and KDJ Death Cross

Based on the 15-minute chart for Tg Therapeutics, the MACD and KDJ indicators have both triggered death crosses at 08/14/2025 15:45. This suggests that the stock price has the potential to continue declining, as the momentum of the stock price is shifting towards the downside and may lead to further decreases.

Title: TG Therapeutics: Mixed Signals and Technical Indicators Suggest Further Downward Pressure

TG Therapeutics (NASDAQ: TGTX) has been in the spotlight recently due to a series of mixed signals and technical indicators that suggest potential further downward pressure on its stock price. The company's stock experienced a significant 2.77% gain on August 13, 2025, but this move was short-lived, with the stock continuing to face downward pressure [2].

The most recent earnings report for Q2 2025 highlighted strong revenue growth, with a 92.1% increase to $141.15 million, driven by a 309.8% increase in net income to $28.19 million [3]. However, the stock has been volatile post-earnings, with a 29.56% month-to-date decline, largely due to an earnings miss that fell short of market expectations by 46.88% [3].

Adding to the mixed signals, the 15-minute chart for Tg Therapeutics has shown both the MACD and KDJ indicators triggering death crosses at 08/14/2025 15:45. This technical indicator suggests a potential shift in momentum towards the downside, which could lead to further decreases in the stock price [2]. The MACD, which is a trend-following momentum indicator, and the KDJ indicator, which is a momentum oscillator, both indicate that the stock price is losing momentum and may continue to decline.

Analysts have maintained a "Hold" rating for Tg Therapeutics, with a Zacks Rank #3, due to inconsistent EPS performance and a high P/E ratio. The stock has only beaten EPS estimates once in the past four quarters, raising concerns about its ability to meet future expectations [3].

The broader market context also plays a role, with Nigeria's foreign direct investment (FDI) declining by 70% and Sterling HoldCo directors investing N341.6 million in company shares, reflecting regional economic dynamics impacting investor confidence [3].

In conclusion, while Tg Therapeutics reported strong financials for Q2 2025, the stock continues to face downward pressure due to technical indicators and earnings misses. Investors should remain cautious and monitor the stock closely for any signs of improvement or further decline.

References:
[1] https://seekingalpha.com/news/4482895-tg-therapeutics-files-automatic-mixed-securities-shelf
[2] https://stockinvest.us/stock/TGTX
[3] https://www.ainvest.com/news/tg-therapeutics-2025-q2-earnings-net-income-surges-309-8-2508/